Detalhe da pesquisa
1.
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
N Engl J Med
; 386(23): 2188-2200, 2022 06 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35443106
2.
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
N Engl J Med
; 384(20): 1885-1898, 2021 05 20.
Artigo
Inglês
| MEDLINE | ID: mdl-33725432
3.
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
N Engl J Med
; 385(25): 2348-2360, 2021 12 16.
Artigo
Inglês
| MEDLINE | ID: mdl-34587382
4.
Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants.
J Infect Dis
; 228(8): 1055-1059, 2023 10 18.
Artigo
Inglês
| MEDLINE | ID: mdl-37280116
5.
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.
Clin Infect Dis
; 76(7): 1247-1256, 2023 04 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36411267
6.
Pango lineage designation and assignment using SARS-CoV-2 spike gene nucleotide sequences.
BMC Genomics
; 23(1): 121, 2022 Feb 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35148677
7.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Lancet
; 396(10267): 1979-1993, 2021 12 19.
Artigo
Inglês
| MEDLINE | ID: mdl-33220855
8.
Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants.
N Engl J Med
; 388(16): 1533-1534, 2023 04 20.
Artigo
Inglês
| MEDLINE | ID: mdl-37018470
9.
Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
Mol Ther
; 25(8): 1917-1932, 2017 08 02.
Artigo
Inglês
| MEDLINE | ID: mdl-28578991
10.
Gene expression in whole lung and pulmonary macrophages reflects the dynamic pathology associated with airway surface dehydration.
BMC Genomics
; 15: 726, 2014 Sep 10.
Artigo
Inglês
| MEDLINE | ID: mdl-25204199
11.
Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12.
Mol Ther Oncol
; 32(1): 200758, 2024 Mar 21.
Artigo
Inglês
| MEDLINE | ID: mdl-38596304
12.
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults.
Hum Vaccin Immunother
; 20(1): 2304974, 2024 Dec 31.
Artigo
Inglês
| MEDLINE | ID: mdl-38512394
13.
The genomic evolutionary dynamics and global circulation patterns of respiratory syncytial virus.
Nat Commun
; 15(1): 3083, 2024 Apr 10.
Artigo
Inglês
| MEDLINE | ID: mdl-38600104
14.
Loss of Cftr function exacerbates the phenotype of Na(+) hyperabsorption in murine airways.
Am J Physiol Lung Cell Mol Physiol
; 304(7): L469-80, 2013 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-23377346
15.
One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): Final analysis of a randomized, placebo-controlled phase 1/2 trial in Japan.
Vaccine
; 41(29): 4199-4205, 2023 06 29.
Artigo
Inglês
| MEDLINE | ID: mdl-37271703
16.
Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection.
Front Immunol
; 14: 1283120, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37901217
17.
AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infection.
Cell Rep Med
; 4(1): 100882, 2023 01 17.
Artigo
Inglês
| MEDLINE | ID: mdl-36610390
18.
Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants.
Microbiol Spectr
; : e0033323, 2023 Mar 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36877050
19.
Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial).
Infect Dis Ther
; 12(12): 2691-2707, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37914983
20.
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.
Lancet Microbe
; 4(11): e863-e874, 2023 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37783221